PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced the appointment of Olivier Regnard to the position of Deputy Chief Executive Officer and Chief Financial Officer, effective immediately. Mr. Regnard brings nearly 20 years of finance, accounting and operational experience to the Company and already has familiarity with Mauna Kea Technologies, having served as a consultant to the Company. In his role, Mr. Regnard will directly oversee Finance, Administration, Information Technology, Human Resources and Operations on a worldwide basis.

Prior to joining Mauna Kea Technologies, Mr. Regnard served as Deputy Chief Executive Officer and Chief Financial Officer at Latécoère, a Euronext Paris-listed leading player in the aeronautics industry with approximately €700 million in annual revenue and more than 5,000 employees. During his tenure at Latécoère, Mr. Regnard was a key contributor to the implementation of the Company’s strategic turn-around plan and led a financial restructuring that included €280 million in capital increase and €278 million in debt reduction. Prior to joining Latécoère, Mr. Regnard spent nearly 15 years at Deloitte, first in Auditing, then in Transaction Services and finally in the Reorganization Services. Mr. Regnard graduated from ESSEC Business School in France and is a certified accountant.

“Since I joined the company, I have been able to fully appreciate the growth potential associated with our unique Cellvizio platform,” declared Olivier Regnard. “The progress realized in the past 24 months by the Company on key success factors such as clinical data, regulatory approvals, reimbursement, as well as the strategic choice to move to a consignment business model in the U.S., has uniquely positioned Mauna Kea for success. I am excited to join the executive team at this important stage in the Company’s development.”

Sacha Loiseau, Ph.D., Founder and Chief Executive Officer of Mauna Kea Technologies, commented, “Since joining the Company, Olivier has demonstrated strong leadership and has already contributed to the operational and financial improvement of the business. I am very pleased to welcome Olivier as Deputy CEO and CFO as we continue to strengthen the Company to execute on our growth strategies.”

About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product, Cellvizio, has received clearance to sell a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico. For more information on Mauna Kea Technologies, visit www.maunakeatech.com

Disclaimer
This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities. Such forward looking statements are based on assumptions that Mauna Kea Technologies considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward- looking statements are subject to numerous risks and uncertainties including the risks set forth in the registration document of Mauna Kea Technologies registered by the French Financial Markets Authority (Autorité des marchés financiers (AMF)) on May 31, 2017 under number D.17-0574 and available on the Company’s website (www.maunakeatech.com), and to the development of economic situation, financial markets, and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Mauna Kea Technologies that differ significantly from the results, financial conditions, performances or achievements expressed in such forward-looking statements. This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for, Mauna Kea Technologies shares in any country.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171017006381/en/